Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Core Insights - Lyell Immunopharma, Inc. is a clinical-stage company focused on developing next-generation CAR T-cell therapies for cancer patients [1][3] - The company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, at 10:00 am ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible afterward [2] Company Overview - Lyell Immunopharma is advancing a pipeline of CAR T-cell therapies targeting hematologic malignancies and solid tumors [3] - The company employs various technologies to enhance CAR T cells, aiming for durable tumor cytotoxicity and consistent clinical responses [3] - Key attributes of Lyell's CAR T cells include resistance to exhaustion, maintenance of stemness, and functionality in challenging tumor microenvironments [3]